Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$13.67
+0.7%
$14.32
$6.99
$17.75
$1.63B1.872.28 million shs1.49 million shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.33
+7.3%
$1.22
$0.92
$22.50
$74.12M0.61312,543 shs567,804 shs
Liquidia Co. stock logo
LQDA
Liquidia
$15.00
+5.8%
$14.72
$8.26
$19.41
$1.28B0.241.08 million shs1.84 million shs
Procaps Group S.A. stock logo
PROC
Procaps Group
$0.95
-40.3%
$0.95
$0.50
$3.78
$107.18M-0.0548,370 shs658,169 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+0.66%+0.07%-7.32%-0.15%+59.14%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
+7.26%+10.83%+1.53%-2.21%-85.37%
Liquidia Co. stock logo
LQDA
Liquidia
+5.78%-3.60%+11.03%-3.16%+20.77%
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00%0.00%0.00%0.00%-65.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.1638 of 5 stars
3.41.00.00.03.31.70.6
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.0074 of 5 stars
3.01.00.04.62.13.31.3
Liquidia Co. stock logo
LQDA
Liquidia
3.6432 of 5 stars
4.51.00.00.03.34.20.6
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.83
Moderate Buy$18.8037.53% Upside
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50313.53% Upside
Liquidia Co. stock logo
LQDA
Liquidia
3.00
Buy$26.6777.78% Upside
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LQDA, PROC, IGMS, and ARQT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/28/2025
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $35.00
5/27/2025
Liquidia Co. stock logo
LQDA
Liquidia
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/23/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
5/21/2025
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/19/2025
Liquidia Co. stock logo
LQDA
Liquidia
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetMarket Perform ➝ Underperform$13.00
5/12/2025
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/12/2025
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/9/2025
Liquidia Co. stock logo
LQDA
Liquidia
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $29.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$212.82M7.66N/AN/A$0.94 per share14.54
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M29.65N/AN/A$3.46 per share0.38
Liquidia Co. stock logo
LQDA
Liquidia
$14.14M90.66N/AN/A$0.73 per share20.55
Procaps Group S.A. stock logo
PROC
Procaps Group
$409.92M0.26N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%8/13/2025 (Estimated)
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$246.42M-$3.27N/AN/AN/A-7,534.03%-155.42%-61.04%8/13/2025 (Estimated)
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.58N/AN/AN/A-765.38%-163.21%-67.14%8/6/2025 (Estimated)
Procaps Group S.A. stock logo
PROC
Procaps Group
$42.54MN/A0.00N/AN/AN/AN/AN/A

Latest LQDA, PROC, IGMS, and ARQT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million
5/8/2025Q1 2025
Liquidia Co. stock logo
LQDA
Liquidia
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/6/2025Q1 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million
3/19/2025Q4 2024
Liquidia Co. stock logo
LQDA
Liquidia
-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million
3/6/2025Q4 2024
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.67
2.46
2.38
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.22
5.22
Liquidia Co. stock logo
LQDA
Liquidia
N/A
6.33
6.33
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Procaps Group S.A. stock logo
PROC
Procaps Group
N/A

Insider Ownership

CompanyInsider Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
9.40%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
Liquidia Co. stock logo
LQDA
Liquidia
26.50%
Procaps Group S.A. stock logo
PROC
Procaps Group
19.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150119.20 million105.93 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.57 millionOptionable
Liquidia Co. stock logo
LQDA
Liquidia
5085.49 million59.16 millionOptionable
Procaps Group S.A. stock logo
PROC
Procaps Group
4,900112.82 million90.37 millionNot Optionable

Recent News About These Companies

Procaps Group appoints new board directors
Procaps Group S.A. (PROCF)
Procaps Group Receives Delisting Notice From Nasdaq
Procaps Group Receives Additional Delinquency Letter
Procaps Group Secures $40 Million Convertible Note Deal

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$13.67 +0.09 (+0.66%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$13.74 +0.07 (+0.51%)
As of 05/29/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.33 +0.09 (+7.26%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.33 0.00 (0.00%)
As of 05/29/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$15.00 +0.82 (+5.78%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$15.16 +0.16 (+1.09%)
As of 05/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Procaps Group stock logo

Procaps Group NASDAQ:PROC

$0.95 -0.64 (-40.28%)
Closing price 02/3/2025
Extended Trading
$0.95 0.00 (0.00%)
As of 02/3/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.